Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

GPIHBP1 and Lipoprotein Lipase, Partners in Plasma Triglyceride Metabolism.

Young SG, Fong LG, Beigneux AP, Allan CM, He C, Jiang H, Nakajima K, Meiyappan M, Birrane G, Ploug M.

Cell Metab. 2019 Jul 2;30(1):51-65. doi: 10.1016/j.cmet.2019.05.023. Review.

PMID:
31269429
2.

Evolution and Medical Significance of LU Domain-Containing Proteins.

Leth JM, Leth-Espensen KZ, Kristensen KK, Kumari A, Lund Winther AM, Young SG, Ploug M.

Int J Mol Sci. 2019 Jun 5;20(11). pii: E2760. doi: 10.3390/ijms20112760. Review.

3.

The PCNA interaction motifs revisited: thinking outside the PIP-box.

Prestel A, Wichmann N, Martins JM, Marabini R, Kassem N, Broendum SS, Otterlei M, Nielsen O, Willemoës M, Ploug M, Boomsma W, Kragelund BB.

Cell Mol Life Sci. 2019 May 27. doi: 10.1007/s00018-019-03150-0. [Epub ahead of print]

PMID:
31134302
4.

Crystal structure of the unoccupied murine urokinase-type plasminogen activator receptor (uPAR) reveals a tightly packed DII-DIII unit.

Liu M, Lin L, Høyer-Hansen G, Ploug M, Li H, Jiang L, Yuan C, Li J, Huang M.

FEBS Lett. 2019 Jun;593(11):1236-1247. doi: 10.1002/1873-3468.13397. Epub 2019 May 15.

PMID:
31044429
5.

Did evolution create a flexible ligand-binding cavity in the urokinase receptor through deletion of a plesiotypic disulfide bond?

Leth JM, Mertens HDT, Leth-Espensen KZ, Jørgensen TJD, Ploug M.

J Biol Chem. 2019 May 3;294(18):7403-7418. doi: 10.1074/jbc.RA119.007847. Epub 2019 Mar 20.

PMID:
30894413
6.

Lipoprotein lipase is active as a monomer.

Beigneux AP, Allan CM, Sandoval NP, Cho GW, Heizer PJ, Jung RS, Stanhope KL, Havel PJ, Birrane G, Meiyappan M, Gill JE 4th, Murakami M, Miyashita K, Nakajima K, Ploug M, Fong LG, Young SG.

Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6319-6328. doi: 10.1073/pnas.1900983116. Epub 2019 Mar 8.

7.

On the mechanism of angiopoietin-like protein 8 for control of lipoprotein lipase activity.

Kovrov O, Kristensen KK, Larsson E, Ploug M, Olivecrona G.

J Lipid Res. 2019 Apr;60(4):783-793. doi: 10.1194/jlr.M088807. Epub 2019 Jan 27.

PMID:
30686789
8.

Origin and diversification of the plasminogen activation system among chordates.

Chana-Muñoz A, Jendroszek A, Sønnichsen M, Wang T, Ploug M, Jensen JK, Andreasen PA, Bendixen C, Panitz F.

BMC Evol Biol. 2019 Jan 17;19(1):27. doi: 10.1186/s12862-019-1353-z.

9.

Structure of the lipoprotein lipase-GPIHBP1 complex that mediates plasma triglyceride hydrolysis.

Birrane G, Beigneux AP, Dwyer B, Strack-Logue B, Kristensen KK, Francone OL, Fong LG, Mertens HDT, Pan CQ, Ploug M, Young SG, Meiyappan M.

Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1723-1732. doi: 10.1073/pnas.1817984116. Epub 2018 Dec 17.

10.

GPIHBP1 autoantibody syndrome during interferon β1a treatment.

Eguchi J, Miyashita K, Fukamachi I, Nakajima K, Murakami M, Kawahara Y, Yamashita T, Ohta Y, Abe K, Nakatsuka A, Mino M, Takase S, Okazaki H, Hegele RA, Ploug M, Hu X, Wada J, Young SG, Beigneux AP.

J Clin Lipidol. 2019 Jan - Feb;13(1):62-69. doi: 10.1016/j.jacl.2018.10.004. Epub 2018 Oct 24.

11.

A disordered acidic domain in GPIHBP1 harboring a sulfated tyrosine regulates lipoprotein lipase.

Kristensen KK, Midtgaard SR, Mysling S, Kovrov O, Hansen LB, Skar-Gislinge N, Beigneux AP, Kragelund BB, Olivecrona G, Young SG, Jørgensen TJD, Fong LG, Ploug M.

Proc Natl Acad Sci U S A. 2018 Jun 26;115(26):E6020-E6029. doi: 10.1073/pnas.1806774115. Epub 2018 Jun 13.

12.

NanoSIMS Analysis of Intravascular Lipolysis and Lipid Movement across Capillaries and into Cardiomyocytes.

He C, Weston TA, Jung RS, Heizer P, Larsson M, Hu X, Allan CM, Tontonoz P, Reue K, Beigneux AP, Ploug M, Holme A, Kilburn M, Guagliardo P, Ford DA, Fong LG, Young SG, Jiang H.

Cell Metab. 2018 May 1;27(5):1055-1066.e3. doi: 10.1016/j.cmet.2018.03.017.

13.

An enzyme-linked immunosorbent assay for measuring GPIHBP1 levels in human plasma or serum.

Miyashita K, Fukamachi I, Nagao M, Ishida T, Kobayashi J, Machida T, Nakajima K, Murakami M, Ploug M, Beigneux AP, Young SG, Nakajima K.

J Clin Lipidol. 2018 Jan - Feb;12(1):203-210.e1. doi: 10.1016/j.jacl.2017.10.022. Epub 2017 Nov 1.

14.

Expression of C4.4A in an In Vitro Human Tissue-Engineered Skin Model.

Jacobsen B, Larouche D, Rochette-Drouin O, Ploug M, Germain L.

Biomed Res Int. 2017;2017:2403072. doi: 10.1155/2017/2403072. Epub 2017 Sep 7.

15.

Expression and crystallographic studies of the D1D2 domains of C4.4A, a homologous protein to the urokinase receptor.

Chen S, Lin L, Yuan C, Gårdsvoll H, Kriegbaum MC, Ploug M, Huang M.

Acta Crystallogr F Struct Biol Commun. 2017 Aug 1;73(Pt 8):486-490. doi: 10.1107/S2053230X17009748. Epub 2017 Jul 27.

16.

The use of a transparent cap in sigmoidoscopy-A randomized controlled clinical trial on pain, time and success rate.

Ploug M, Poulsen JK, Jensen HQ, Achiam M.

Indian J Gastroenterol. 2017 Jul;36(4):318-322. doi: 10.1007/s12664-017-0776-y. Epub 2017 Aug 1.

PMID:
28762140
17.

GPIHBP1 autoantibodies in a patient with unexplained chylomicronemia.

Hu X, Dallinga-Thie GM, Hovingh GK, Chang SY, Sandoval NP, Dang TLP, Fukamachi I, Miyashita K, Nakajima K, Murakami M, Fong LG, Ploug M, Young SG, Beigneux AP.

J Clin Lipidol. 2017 Jul - Aug;11(4):964-971. doi: 10.1016/j.jacl.2017.05.017. Epub 2017 Jun 13.

18.

Autoantibodies against GPIHBP1 as a Cause of Hypertriglyceridemia.

Beigneux AP, Miyashita K, Ploug M, Blom DJ, Ai M, Linton MF, Khovidhunkit W, Dufour R, Garg A, McMahon MA, Pullinger CR, Sandoval NP, Hu X, Allan CM, Larsson M, Machida T, Murakami M, Reue K, Tontonoz P, Goldberg IJ, Moulin P, Charrière S, Fong LG, Nakajima K, Young SG.

N Engl J Med. 2017 Apr 27;376(17):1647-1658. doi: 10.1056/NEJMoa1611930. Epub 2017 Apr 5.

19.

The angiopoietin-like protein ANGPTL4 catalyzes unfolding of the hydrolase domain in lipoprotein lipase and the endothelial membrane protein GPIHBP1 counteracts this unfolding.

Mysling S, Kristensen KK, Larsson M, Kovrov O, Bensadouen A, Jørgensen TJ, Olivecrona G, Young SG, Ploug M.

Elife. 2016 Dec 8;5. pii: e20958. doi: 10.7554/eLife.20958.

20.

Monoclonal antibodies that bind to the Ly6 domain of GPIHBP1 abolish the binding of LPL.

Hu X, Sleeman MW, Miyashita K, Linton MF, Allan CM, He C, Larsson M, Tu Y, Sandoval NP, Jung RS, Mapar A, Machida T, Murakami M, Nakajima K, Ploug M, Fong LG, Young SG, Beigneux AP.

J Lipid Res. 2017 Jan;58(1):208-215. doi: 10.1194/jlr.M072462. Epub 2016 Nov 15.

21.

Mobility of "HSPG-bound" LPL explains how LPL is able to reach GPIHBP1 on capillaries.

Allan CM, Larsson M, Jung RS, Ploug M, Bensadoun A, Beigneux AP, Fong LG, Young SG.

J Lipid Res. 2017 Jan;58(1):216-225. doi: 10.1194/jlr.M072520. Epub 2016 Nov 3.

22.

An LPL-specific monoclonal antibody, 88B8, that abolishes the binding of LPL to GPIHBP1.

Allan CM, Larsson M, Hu X, He C, Jung RS, Mapar A, Voss C, Miyashita K, Machida T, Murakami M, Nakajima K, Bensadoun A, Ploug M, Fong LG, Young SG, Beigneux AP.

J Lipid Res. 2016 Oct;57(10):1889-1898. Epub 2016 Aug 5.

23.

Tissue Inhibitor of Metalloproteinase-1 Is Confined to Tumor-Associated Myofibroblasts and Is Increased With Progression in Gastric Adenocarcinoma.

Alpízar-Alpízar W, Laerum OD, Christensen IJ, Ovrebo K, Skarstein A, Høyer-Hansen G, Ploug M, Illemann M.

J Histochem Cytochem. 2016 Aug;64(8):483-94. doi: 10.1369/0022155416656173. Epub 2016 Jul 1.

24.

GPIHBP1 and Plasma Triglyceride Metabolism.

Fong LG, Young SG, Beigneux AP, Bensadoun A, Oberer M, Jiang H, Ploug M.

Trends Endocrinol Metab. 2016 Jul;27(7):455-469. doi: 10.1016/j.tem.2016.04.013. Epub 2016 May 14. Review.

25.

C4.4A gene ablation is compatible with normal epidermal development and causes modest overt phenotypes.

Kriegbaum MC, Jacobsen B, Füchtbauer A, Hansen GH, Christensen IJ, Rundsten CF, Persson M, Engelholm LH, Madsen AN, Di Meo I, Lund IK, Holst B, Kjaer A, Lærum OD, Füchtbauer EM, Ploug M.

Sci Rep. 2016 May 12;6:25833. doi: 10.1038/srep25833.

26.

Peptide-Based Optical uPAR Imaging for Surgery: In Vivo Testing of ICG-Glu-Glu-AE105.

Juhl K, Christensen A, Persson M, Ploug M, Kjaer A.

PLoS One. 2016 Feb 1;11(2):e0147428. doi: 10.1371/journal.pone.0147428. eCollection 2016.

27.

The acidic domain of the endothelial membrane protein GPIHBP1 stabilizes lipoprotein lipase activity by preventing unfolding of its catalytic domain.

Mysling S, Kristensen KK, Larsson M, Beigneux AP, Gårdsvoll H, Fong LG, Bensadouen A, Jørgensen TJ, Young SG, Ploug M.

Elife. 2016 Jan 3;5:e12095. doi: 10.7554/eLife.12095.

28.

First-in-human uPAR PET: Imaging of Cancer Aggressiveness.

Persson M, Skovgaard D, Brandt-Larsen M, Christensen C, Madsen J, Nielsen CH, Thurison T, Klausen TL, Holm S, Loft A, Berthelsen AK, Ploug M, Pappot H, Brasso K, Kroman N, Højgaard L, Kjaer A.

Theranostics. 2015 Sep 13;5(12):1303-16. doi: 10.7150/thno.12956. eCollection 2015.

29.

Mapping the topographic epitope landscape on the urokinase plasminogen activator receptor (uPAR) by surface plasmon resonance and X-ray crystallography.

Zhao B, Gandhi S, Yuan C, Luo Z, Li R, Gårdsvoll H, de Lorenzi V, Sidenius N, Huang M, Ploug M.

Data Brief. 2015 Sep 4;5:107-13. doi: 10.1016/j.dib.2015.08.027. eCollection 2015 Dec.

30.

Heterogeneity in the properties of mutant secreted lymphocyte antigen 6/urokinase receptor-related protein 1 (SLURP1) in Mal de Meleda.

Adeyo O, Oberer M, Ploug M, Fong LG, Young SG, Beigneux AP.

Br J Dermatol. 2015 Oct;173(4):1066-9. doi: 10.1111/bjd.13868. Epub 2015 Aug 19. No abstract available.

31.

Urokinase receptor cleavage correlates with tumor volume in a transgenic mouse model of breast cancer.

Thurison T, Almholt K, Gårdsvoll H, Ploug M, Høyer-Hansen G, Lund IK.

Mol Carcinog. 2016 May;55(5):717-31. doi: 10.1002/mc.22316. Epub 2015 Mar 25.

PMID:
25809119
32.

Protein-binding RNA aptamers affect molecular interactions distantly from their binding sites.

Dupont DM, Thuesen CK, Bøtkjær KA, Behrens MA, Dam K, Sørensen HP, Pedersen JS, Ploug M, Jensen JK, Andreasen PA.

PLoS One. 2015 Mar 20;10(3):e0119207. doi: 10.1371/journal.pone.0119207. eCollection 2015. Erratum in: PLoS One. 2015;10(4):e0126782.

33.

Stabilizing a flexible interdomain hinge region harboring the SMB binding site drives uPAR into its closed conformation.

Zhao B, Gandhi S, Yuan C, Luo Z, Li R, Gårdsvoll H, de Lorenzi V, Sidenius N, Huang M, Ploug M.

J Mol Biol. 2015 Mar 27;427(6 Pt B):1389-1403. doi: 10.1016/j.jmb.2015.01.022. Epub 2015 Feb 7.

PMID:
25659907
34.

Expression of the Ly6/uPAR-domain proteins C4.4A and Haldisin in non-invasive and invasive skin lesions.

Kriegbaum MC, Clausen OP, Lærum OD, Ploug M.

J Histochem Cytochem. 2015 Feb;63(2):142-54. doi: 10.1369/0022155414563107. Epub 2014 Nov 20.

35.

GPIHBP1 missense mutations often cause multimerization of GPIHBP1 and thereby prevent lipoprotein lipase binding.

Beigneux AP, Fong LG, Bensadoun A, Davies BS, Oberer M, Gårdsvoll H, Ploug M, Young SG.

Circ Res. 2015 Feb 13;116(4):624-32. doi: 10.1161/CIRCRESAHA.116.305085. Epub 2014 Nov 11.

36.

C4.4A as a biomarker in pulmonary adenocarcinoma and squamous cell carcinoma.

Jacobsen B, Kriegbaum MC, Santoni-Rugiu E, Ploug M.

World J Clin Oncol. 2014 Oct 10;5(4):621-32. doi: 10.5306/wjco.v5.i4.621. Review.

37.

uPAR targeted radionuclide therapy with (177)Lu-DOTA-AE105 inhibits dissemination of metastatic prostate cancer.

Persson M, Juhl K, Rasmussen P, Brandt-Larsen M, Madsen J, Ploug M, Kjaer A.

Mol Pharm. 2014 Aug 4;11(8):2796-806. doi: 10.1021/mp500177c. Epub 2014 Jul 1.

PMID:
24955765
38.

Multimerization of glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1 (GPIHBP1) and familial chylomicronemia from a serine-to-cysteine substitution in GPIHBP1 Ly6 domain.

Plengpanich W, Young SG, Khovidhunkit W, Bensadoun A, Karnman H, Ploug M, Gårdsvoll H, Leung CS, Adeyo O, Larsson M, Muanpetch S, Charoen S, Fong LG, Niramitmahapanya S, Beigneux AP.

J Biol Chem. 2014 Jul 11;289(28):19491-9. doi: 10.1074/jbc.M114.558528. Epub 2014 May 20.

39.

Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice.

Cathelin D, Placier S, Ploug M, Verpont MC, Vandermeersch S, Luque Y, Hertig A, Rondeau E, Mesnard L.

J Am Soc Nephrol. 2014 Aug;25(8):1662-8. doi: 10.1681/ASN.2013040425. Epub 2014 May 1.

40.

Tousled-like kinases phosphorylate Asf1 to promote histone supply during DNA replication.

Klimovskaia IM, Young C, Strømme CB, Menard P, Jasencakova Z, Mejlvang J, Ask K, Ploug M, Nielsen ML, Jensen ON, Groth A.

Nat Commun. 2014 Mar 6;5:3394. doi: 10.1038/ncomms4394.

41.

Electrochemical reduction of disulfide-containing proteins for hydrogen/deuterium exchange monitored by mass spectrometry.

Mysling S, Salbo R, Ploug M, Jørgensen TJ.

Anal Chem. 2014 Jan 7;86(1):340-5. doi: 10.1021/ac403269a. Epub 2013 Dec 23.

PMID:
24251601
42.

Improved PET imaging of uPAR expression using new (64)Cu-labeled cross-bridged peptide ligands: comparative in vitro and in vivo studies.

Persson M, Hosseini M, Madsen J, Jørgensen TJ, Jensen KJ, Kjaer A, Ploug M.

Theranostics. 2013 Aug 3;3(9):618-32. doi: 10.7150/thno.6810. eCollection 2013.

43.

The urokinase receptor homolog Haldisin is a novel differentiation marker of stratum granulosum in squamous epithelia.

Gårdsvoll H, Kriegbaum MC, Hertz EP, Alpízar-Alpízar W, Ploug M.

J Histochem Cytochem. 2013 Nov;61(11):802-13. doi: 10.1369/0022155413501879. Epub 2013 Jul 29.

44.
45.

Targeting of peptide conjugated magnetic nanoparticles to urokinase plasminogen activator receptor (uPAR) expressing cells.

Hansen L, Larsen EK, Nielsen EH, Iversen F, Liu Z, Thomsen K, Pedersen M, Skrydstrup T, Nielsen NC, Ploug M, Kjems J.

Nanoscale. 2013 Sep 7;5(17):8192-201. doi: 10.1039/c3nr32922d.

PMID:
23835641
46.

Ly6/uPAR-related protein C4.4A as a marker of solid growth pattern and poor prognosis in lung adenocarcinoma.

Jacobsen B, Muley T, Meister M, Dienemann H, Christensen IJ, Santoni-Rugiu E, Lærum OD, Ploug M.

J Thorac Oncol. 2013 Feb;8(2):152-60. doi: 10.1097/JTO.0b013e318279d503.

47.

Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism.

Botkjaer KA, Deryugina EI, Dupont DM, Gårdsvoll H, Bekes EM, Thuesen CK, Chen Z, Ploug M, Quigley JP, Andreasen PA.

Mol Cancer Res. 2012 Dec;10(12):1532-43. doi: 10.1158/1541-7786.MCR-12-0349. Epub 2012 Oct 4. Erratum in: Mol Cancer Res. 2013 Aug;11(8):964. Chen, Zhou [corrected to Chen, Zhuo].

48.

Hydrogen/deuterium exchange mass spectrometry reveals specific changes in the local flexibility of plasminogen activator inhibitor 1 upon binding to the somatomedin B domain of vitronectin.

Trelle MB, Hirschberg D, Jansson A, Ploug M, Roepstorff P, Andreasen PA, Jørgensen TJ.

Biochemistry. 2012 Oct 16;51(41):8256-66. doi: 10.1021/bi3008998. Epub 2012 Oct 4.

PMID:
22957734
49.

A flexible multidomain structure drives the function of the urokinase-type plasminogen activator receptor (uPAR).

Mertens HD, Kjaergaard M, Mysling S, Gårdsvoll H, Jørgensen TJ, Svergun DI, Ploug M.

J Biol Chem. 2012 Oct 5;287(41):34304-15. doi: 10.1074/jbc.M112.398404. Epub 2012 Aug 15.

50.

New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts.

Persson M, Rasmussen P, Madsen J, Ploug M, Kjaer A.

Nucl Med Biol. 2012 Oct;39(7):962-9. doi: 10.1016/j.nucmedbio.2012.05.007. Epub 2012 Jun 26.

PMID:
22739362

Supplemental Content

Support Center